Novartis inks AI collaboration with Generate

USA-based Generate:Biomedicines (Generate) today announced a multi-target collaboration with Swiss pharm giant Novartis (NOVN; VX) to discover and develop protein therapeutics across multiple disease areas.

The collaboration leverages Generate’s proprietary generative AI platform, “The Generate Platform,” to create potentially first- and best-in-class molecules through AI-based optimization and de novo generation.

The collaboration will combine The Generate Platform, which integrates machine learning with high-throughput experimental validation, with Novartis expertise and capabilities in target biology, biologics development, and clinical development to create novel therapeutics and to accelerate the pace of drug discovery and development.